Related Experiment Video
Updated: May 17, 2025

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Initiating renin-angiotensin system inhibitors in chronic kidney disease
Anna Katharina Forbes1, Hugh Gallagher2,3
1Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Abstract:
Chronic kidney disease (CKD) is a heterogeneous group of disorders characterised by abnormalities in kidney structure or function, present for at least 3 months. Renin-angiotensin system (RAS) inhibitors are established treatments in the management of CKD, reducing the risk of adverse kidney and cardiovascular events. Despite an extensive evidence base and decades of clinical experience, they remain underused, underdosed and frequently discontinued due to concerns about changes in kidney function and hyperkalaemia. In this article, we provide an overview of initiating RAS inhibitors in adults with CKD, highlight current guideline recommendations and offer a practical approach to dealing with the challenges associated with their use.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Hormonal Regulation
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Diuretics

